Welcome to our dedicated page for Jaguar Health news (Ticker: JAGX), a resource for investors and traders seeking the latest updates and insights on Jaguar Health stock.
Jaguar Health, Inc. (NASDAQ: JAGX) is a commercial-stage pharmaceuticals company specializing in the development of novel prescription medicines sustainably derived from natural plant sources in rainforest areas. The company's primary focus is on addressing gastrointestinal (GI) distress in both humans and animals, with an emphasis on chronic debilitating diarrhea and associated symptoms such as urgency, bowel incontinence, and cramping pain.
Jaguar Health operates through several subsidiaries, including Napo Pharmaceuticals, Inc., which develops and commercializes proprietary human GI pharmaceuticals globally. One of its flagship products, Mytesi® (crofelemer), is FDA-approved for symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company’s lead animal prescription drug candidate, Canalevia™, targets forms of diarrhea in dogs, while Equilevia™ supports total gut health in equine athletes.
In addition, Jaguar Health, through its Napo Pharmaceuticals subsidiary, is advancing the development of crofelemer with the ongoing OnTarget study, a pivotal Phase 3 clinical trial aimed at the preventive treatment of chemotherapy-induced overactive bowel (CIOB) in adults with cancer on targeted therapy. Crofelemer has also been designated an Orphan Drug by the FDA and European Medicines Agency for short bowel syndrome (SBS) and microvillus inclusion disease (MVID).
Jaguar Health’s commitment to cancer supportive care is showcased through its preparation to launch Gelclair®, an FDA-approved oral mucositis prescription product, in Q3 2024. This initiative is part of their broader strategy to support cancer patients facing severe treatment side effects.
Beyond GI distress, Jaguar Health has a joint venture called Magdalena Biosciences, in collaboration with Filament Health Corp. This venture focuses on developing plant-based prescription medicines for mental health indications. A recent out-licensing agreement with Magdalena includes a botanical drug candidate for potential schizophrenia and psychoses indications.
Jaguar Health’s financial performance reflects consistent growth, with Q1 2024 revenue at approximately $2.4 million, showing a 20% increase from Q1 2023. Despite operational losses, the company continues to invest in research and development, particularly for rare disease treatments.
For more information, visit Jaguar Health, Napo Pharmaceuticals, Napo Therapeutics, and Magdalena Biosciences. Stay connected with Jaguar Health on LinkedIn, X (formerly Twitter), and Instagram.
Jaguar Health announced that the merger between its Italian subsidiary, Napo EU S.p.A., and Dragon SPAC S.p.A. is set to be completed within a week. The merger has received clearance from the Italian government under the 'Golden Powers' process. The new entity will hold an exclusive license for the crofelemer pipeline in Europe, with significant up-front fees and royalties due to Jaguar. Napo EU will primarily focus on obtaining conditional marketing authorization for crofelemer, aimed at treating short bowel syndrome.
Jaguar Health (NASDAQ:JAGX) announced updates on its crofelemer drug candidates and the merger with Dragon SPAC and Napo EU. The required regulatory notification for the merger has been submitted to the Italian government. The HALT-D study results on crofelemer for diarrhea prevention in breast cancer patients will be presented at the San Antonio Breast Cancer Symposium in December 2021. Additionally, discussions with the FDA regarding NP-300 for acute diarrhea relief were positive, and Canalevia for treating dogs' chemotherapy-induced diarrhea is set to launch in December 2021.
Jaguar Health, Inc. (JAGX) announces that Founder and CEO Lisa Conte will receive an Impact Award from Pure Earth for her dedication to supporting Indigenous communities and sustainable medicine. The award ceremony is set for October 4, 2021, in New York City. Under Conte's leadership, Jaguar developed crofelemer, the first FDA-approved plant-based oral medicine from the Croton lechleri tree, with over 800,000 trees planted. Pure Earth, recognized for its global pollution reduction efforts, praises Conte as a visionary in pharmaceuticals.
Jaguar Health (NASDAQ:JAGX) announced an R&D Showcase webinar on September 29, 2021, focusing on cancer therapy-related diarrhea (CTD). Hosted by Ladenburg Thalmann, the webinar will feature insights from leading oncologists and Jaguar's CEO Lisa Conte. The event aims to highlight the importance of supportive care for cancer patients struggling with diarrhea due to therapy. It is open to investors and financial analysts. Jaguar's subsidiaries focus on plant-based gastrointestinal medicines.
Jaguar Health announced on September 21, 2021, that it received confirmation from the FDA's Center for Veterinary Medicine that the Target Animal Safety section of its application for the conditional approval of Canalevia for chemotherapy-induced diarrhea (CID) in dogs is complete. Canalevia, an oral plant-based drug, aims to help dogs undergoing chemotherapy, addressing a significant issue as approximately 40% of treated dogs experience diarrhea that may affect treatment. Launch is expected in December 2021.
Jaguar Health (NASDAQ:JAGX) announced an investor webcast scheduled for September 20, 2021, at 8:30 AM Eastern Time. The company is also launching an educational awareness contest in honor of Indigenous Peoples' Day on October 11, 2021. This fifth contest aims to honor Indigenous healers and will award a winner a book on ethnobotany. Participants must submit answers to multiple-choice questions by 9:00 AM on the contest date. Jaguar Health focuses on developing plant-based pharmaceuticals for gastrointestinal issues.
Jaguar Health (NASDAQ:JAGX) announced that the European Medicines Agency (EMA) has accepted the orphan drug designation application for crofelemer for treating short bowel syndrome with intestinal failure (SBS-IF). This acceptance initiates a formal review process by the EMA's Committee for Orphan Medicinal Products. The company aims to secure conditional marketing authorization in Europe, focusing on this critical orphan disease. Crofelemer, previously designated as an orphan drug by the FDA for SBS in the U.S., has significant market potential, especially given that approximately 10,000 to 20,000 patients may be affected in both the U.S. and Europe.
Jaguar Health (NASDAQ:JAGX) has successfully completed a $776,200 private placement of approximately 309,242 shares of Common Stock. This offering, led by impact investor Josh Mailman and including Jaguar's CEO and CFO, was priced at a premium to market. The company's subsidiary, Napo EU, aims to expand access to its drug crofelemer in Europe, specifically targeting short bowel syndrome. A merger with Dragon SPAC is pending regulatory approval, expected by early October 2021. Ismaila Sougoufara has been promoted to Senior Director, Corporate Controller.
Jaguar Health has appointed Karen J. Brunke, Ph.D., as Executive VP of Corporate and Business Development and Chip Whitlow as Marketing Director. These appointments underscore the company's commitment to advancing crofelemer for treating chemotherapy-induced diarrhea (CID) in dogs, with expected approval in Q4 2021. The appointments aim to foster partnerships for crofelemer's potential human applications and enhance the ongoing commercialization efforts. With an increase in canine cancer diagnoses, these developments signify an important market opportunity for Jaguar.
Jaguar Health, Inc. (NASDAQ:JAGX) announced a 1-for-3 reverse stock split of its common stock, effective September 8, 2021. This decision follows approval from a majority of shareholders at a special meeting held in December 2020. The reverse split aims to align Jaguar's stock price with institutional investing standards, enhancing its appeal to long-term investors. Post-split, every three shares will convert to one, and fractional shares will be compensated with cash. Jaguar continues its focus on developing plant-based non-opioid medicines for gastrointestinal issues.
FAQ
What is the current stock price of Jaguar Health (JAGX)?
What is the market cap of Jaguar Health (JAGX)?
What is Jaguar Health, Inc.?
What are the main products of Jaguar Health?
What is Mytesi® used for?
What is the OnTarget study?
What recent achievements has Jaguar Health made?
What is the focus of Magdalena Biosciences?
What are the financial highlights for Jaguar Health in Q1 2024?
What sustainability practices does Jaguar Health follow?
How can I stay updated on Jaguar Health's developments?
What is Gelclair® and its use?
